Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd..
BACKGROUND: t-AML occurs after a primary malignancy treatment and retains a poor prognosis.
AIMS: To determine the impact of primary malignancies, therapeutic strategies, and prognostic factors on clinical outcomes of t-AML.
RESULTS: A total of 112 adult patients were included in this study. Fifty-Five patients received intensive chemotherapy (IC), 33 non-IC, and 24 best supportive care. At t-AML diagnosis, 42% and 44% of patients presented an unfavorable karyotype and unfavorable 2010 ELN risk profile, respectively. Among treated patients (n = 88), 43 (49%) achieved complete remission: four out of 33 (12%) and 39 out of 55 (71%) in non-IC and IC groups, respectively. With a median follow-up of 5.5 months, the median overall survival (OS) and disease-free survival (DFS) for the whole population were 9 months and 6.3 months, respectively, and for the 88 treated patients 13.5 months and 8.2 months, respectively. Univariate analysis on OS and DFS showed a significant impact of high white blood cells (WBC) and blast counts at diagnosis, unfavorable karyotype and ELN classification. Multivariate analysis showed a negative impact of WBC count at diagnosis and a positive impact of chemotherapy on OS and DFS in the whole population. It also showed a negative impact of previous auto-HCT and high WBC count on OS and DFS and of IC on OS in treated patients which disappeared when we considered only confounding variables (age, previous cancers, marrow blasts, and 2010 ELN classification). In a pair-matched analysis comparing IC treated t-AML with de novo AML, there was no difference of OS and DFS between the two populations.
CONCLUSION: We showed, in this study that t-AML patients with unfavorable features represented almost half of the population. Best outcomes obtained in patients receiving IC must be balanced by known confounding variables and should be improved by using new innovative agents and therapeutic strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cancer medicine - 12(2023), 16 vom: 07. Aug., Seite 16929-16944 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Belhabri, Amine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical outcome |
|---|
| Anmerkungen: |
Date Completed 15.09.2023 Date Revised 16.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cam4.6322 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360480403 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360480403 | ||
| 003 | DE-627 | ||
| 005 | 20231226083113.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cam4.6322 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360480403 | ||
| 035 | |a (NLM)37548369 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Belhabri, Amine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.09.2023 | ||
| 500 | |a Date Revised 16.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: t-AML occurs after a primary malignancy treatment and retains a poor prognosis | ||
| 520 | |a AIMS: To determine the impact of primary malignancies, therapeutic strategies, and prognostic factors on clinical outcomes of t-AML | ||
| 520 | |a RESULTS: A total of 112 adult patients were included in this study. Fifty-Five patients received intensive chemotherapy (IC), 33 non-IC, and 24 best supportive care. At t-AML diagnosis, 42% and 44% of patients presented an unfavorable karyotype and unfavorable 2010 ELN risk profile, respectively. Among treated patients (n = 88), 43 (49%) achieved complete remission: four out of 33 (12%) and 39 out of 55 (71%) in non-IC and IC groups, respectively. With a median follow-up of 5.5 months, the median overall survival (OS) and disease-free survival (DFS) for the whole population were 9 months and 6.3 months, respectively, and for the 88 treated patients 13.5 months and 8.2 months, respectively. Univariate analysis on OS and DFS showed a significant impact of high white blood cells (WBC) and blast counts at diagnosis, unfavorable karyotype and ELN classification. Multivariate analysis showed a negative impact of WBC count at diagnosis and a positive impact of chemotherapy on OS and DFS in the whole population. It also showed a negative impact of previous auto-HCT and high WBC count on OS and DFS and of IC on OS in treated patients which disappeared when we considered only confounding variables (age, previous cancers, marrow blasts, and 2010 ELN classification). In a pair-matched analysis comparing IC treated t-AML with de novo AML, there was no difference of OS and DFS between the two populations | ||
| 520 | |a CONCLUSION: We showed, in this study that t-AML patients with unfavorable features represented almost half of the population. Best outcomes obtained in patients receiving IC must be balanced by known confounding variables and should be improved by using new innovative agents and therapeutic strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a clinical outcome | |
| 650 | 4 | |a real-life management | |
| 650 | 4 | |a therapy-related AML | |
| 700 | 1 | |a Heiblig, Mael |e verfasserin |4 aut | |
| 700 | 1 | |a Morisset, Stephane |e verfasserin |4 aut | |
| 700 | 1 | |a Vila, Liliana |e verfasserin |4 aut | |
| 700 | 1 | |a Santana, Clémence |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolas-Virelizier, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Hayette, Sandrine |e verfasserin |4 aut | |
| 700 | 1 | |a Tigaud, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Plesa, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Labussiere-Wallet, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Sobh, Mohamad |e verfasserin |4 aut | |
| 700 | 1 | |a Michallet, Anne-Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Marie, Balsat |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolini, Franck-Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Guillermin, Yann |e verfasserin |4 aut | |
| 700 | 1 | |a Gaëlle, Fossard |e verfasserin |4 aut | |
| 700 | 1 | |a Lebras, Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Rey, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Jauffret-Bertholon, Lucie |e verfasserin |4 aut | |
| 700 | 1 | |a Laude, Marie-Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Sandrine, Loron |e verfasserin |4 aut | |
| 700 | 1 | |a Michallet, Mauricette |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer medicine |d 2012 |g 12(2023), 16 vom: 07. Aug., Seite 16929-16944 |w (DE-627)NLM224388460 |x 2045-7634 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:16 |g day:07 |g month:08 |g pages:16929-16944 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cam4.6322 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 16 |b 07 |c 08 |h 16929-16944 | ||